Aron M. Knickerbocker
Chief Executive Officer bei Aulos Bioscience, Inc.
Profil
Aron M.
Knickerbocker is currently the President, Chief Executive Officer & Director at Aulos Bioscience, Inc. He is also the Chairman at KAHR Medical Ltd.
and a Director at Phenomic AI, Inc. Previously, he served as the President, Chief Executive Officer & Director at Five Prime Therapeutics, Inc. from 2018 to 2019.
He was also the Chairman & Chief Executive Officer at Rayzebio, Inc. Additionally, he held positions as the Director-Commercial Development at ALZA Corp.
from 2000 to 2001, Senior Director-Business Development at Genentech, Inc. from 2005 to 2009, and Senior Manager-Corporate Development at Amgen, Inc. from 1996 to 2000.
Mr. Knickerbocker started his career as a Scientist at Bristol Myers Squibb Co. He completed his undergraduate degree at Washington University in St. Louis in 1990 and obtained an MBA from the University of Michigan in 1996.
Aktive Positionen von Aron M. Knickerbocker
| Unternehmen | Position | Beginn |
|---|---|---|
KAHR Medical Ltd.
 KAHR Medical Ltd. Pharmaceuticals: MajorHealth Technology KAHR Medical Ltd. develops novel fusion protein pharmaceuticals for the treatment of cancer and autoimmune diseases. Its drug pipeline is built around the signal converter proteins a unique class of multi-functional therapeutic agents that convert signals sent from one cell to another. The firm?s therapeutic proteins integrate two functional units, enabling each one to elicit multiple cooperative functional endpoints. The company was founded by Mark L. Tykocinski in 2005 and is headquartered in Jerusalem, Israel. | Chairman | - |
Aulos Bioscience, Inc.
 Aulos Bioscience, Inc. BiotechnologyHealth Technology Aulos Bioscience, Inc. operates as a biotechnology firm. The company is headquartered in Cambridge, MA. | Chief Executive Officer | 15.03.2021 |
Phenomic AI, Inc.
 Phenomic AI, Inc. Packaged SoftwareTechnology Services Phenomic AI, Inc. develops machine-learning technology for drug discovery. It provides application of deep learning to biological imaging screens and chemo-informatics. The company was founded by Oren Kraus and Sam Cooper and is headquartered in Toronto, Canada. | Director/Board Member | - |
Ehemalige bekannte Positionen von Aron M. Knickerbocker
| Unternehmen | Position | Ende |
|---|---|---|
| FIVE PRIME THERAPEUTICS, INC. | Chief Executive Officer | 19.09.2019 |
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Corporate Officer/Principal | 01.09.2009 |
| ALZA CORPORATION | Corporate Officer/Principal | 01.01.2001 |
| AMGEN INC. | Corporate Officer/Principal | 01.01.2000 |
| RAYZEBIO, INC. | Chief Executive Officer | - |
Ausbildung von Aron M. Knickerbocker
| Washington University in St. Louis | Undergraduate Degree |
| University of Michigan | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 3 |
|---|---|
| AMGEN INC. | Health Technology |
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| RAYZEBIO, INC. | Health Technology |
| Private Unternehmen | 6 |
|---|---|
ALZA Corp.
 ALZA Corp. Pharmaceuticals: MajorHealth Technology ALZA Corp. provides drug delivery solutions and develops pharmaceutical products. The company applies its delivery technologies to develop pharmaceutical products with enhanced therapeutic value for its own portfolio and for many of the world's leading pharmaceutical companies. The company was founded by Martin Gerstel and Alejandro Zaffaroni in 1968 and is headquartered in Vacaville, CA. | Health Technology |
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Health Technology |
Five Prime Therapeutics, Inc.
 Five Prime Therapeutics, Inc. BiotechnologyHealth Technology Five Prime Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of novel protein therapeutics. Its product candidates includes, Cabiralizumab (FPA008), Bemarituzumab (FPA144), and FPA150. The FPA008 is an antibody that inhibits colony stimulating factor-1, or CSF1, receptor, or CSF1R, that are developing in rheumatoid arthritis and plan to clinically develop in pigmented villonodular synovitis, or PVNS, and in combination with nivolumab in multiple cancers. The FPA144 is an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, that are developing to treat patients with gastric cancer. The FPA150 is a CD8 T cell checkpoint which targets B7-H4 that is developing as a monotherapy in multiple cancers. The company was founded by Lewis T. Williams in December 2001 and is headquartered in South San Francisco, C. | Health Technology |
KAHR Medical Ltd.
KAHR Medical Ltd. Pharmaceuticals: MajorHealth Technology KAHR Medical Ltd. develops novel fusion protein pharmaceuticals for the treatment of cancer and autoimmune diseases. Its drug pipeline is built around the signal converter proteins a unique class of multi-functional therapeutic agents that convert signals sent from one cell to another. The firm?s therapeutic proteins integrate two functional units, enabling each one to elicit multiple cooperative functional endpoints. The company was founded by Mark L. Tykocinski in 2005 and is headquartered in Jerusalem, Israel. | Health Technology |
Phenomic AI, Inc.
Phenomic AI, Inc. Packaged SoftwareTechnology Services Phenomic AI, Inc. develops machine-learning technology for drug discovery. It provides application of deep learning to biological imaging screens and chemo-informatics. The company was founded by Oren Kraus and Sam Cooper and is headquartered in Toronto, Canada. | Technology Services |
Aulos Bioscience, Inc.
Aulos Bioscience, Inc. BiotechnologyHealth Technology Aulos Bioscience, Inc. operates as a biotechnology firm. The company is headquartered in Cambridge, MA. | Health Technology |
